
PHAR vs AKTS
$PHAR vs $AKTS head to head: price, market cap, valuation, dividend, free float, relative volume and how actively each trades. The bigger value in the size rows is bolded. Tap either ticker for its live chart, full ownership breakdown and real-time alerts.
PHAR vs AKTS: trend, levels and the market
One year to 2026-11-18, against the S&P 500 (+5.2%). Split-adjusted daily closes.
- ·AKTS is the weaker of the two on trend, below both its 50- and 200-day averages, while PHAR has held above one of them.
- ·Neither kept up with the market over the past year: PHAR -33.3% and AKTS -28.1%, against the S&P 500 at +5.2%.
- ·The last month has flipped the order: PHAR leads over the month (+28% against +0.1%) even though AKTS leads over the year.
- ·PHAR has support 6% below at $11.73; AKTS has no tested support within 35% under its price.
Support and resistance are daily prices the stock has turned at three or more times, within 35% of the price. The loading zone is the nearby price where the heaviest volume traded. These describe where a stock has been, not where it will go. Not investment advice.
PHAR vs AKTS: the quick read
- ·AKTS is the larger company by market cap ($895M vs $884M).
- ·AKTS has been more active on our scanner (71 vs 4 alerts in 30 days).
- ·AKTS has the smaller float (37.3M vs 70.8M), which tends to mean sharper, more volatile moves.
- ·Both are pharmaceutical preparations names, so this is a like-for-like comparison and sector news tends to move them together.
- ·AKTS draws far more of our scanner's attention, 71 unusual-volume alerts in 30 days against 4, so it is the more actively traded of the two by some distance.
- ·They are closely matched in size, within 1% of each other on market cap, which makes the rest of this table the interesting part.
Objective differences only. Not investment advice.
Watching PHAR or AKTS? Get each morning’s movers by email
Free daily email of the top plays and unusual-volume alerts our scanner flags. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Frequently asked questions
Everything you need to know comparing PHAR and AKTS on TheDesperateTrader.
- Is PHAR or AKTS the better stock?
- "Better" depends on your goal, and these two are not alike. AKTS is the larger company by market cap ($895M vs $884M). AKTS has been more active on our scanner (71 vs 4 alerts in 30 days). AKTS has the smaller float (37.3M vs 70.8M), which tends to mean sharper, more volatile moves. Those are the measured differences, not a recommendation, and nothing here is investment advice.
- What is the difference between PHAR and AKTS?
- The differences that matter: they are similar in size ($884M vs $895M); they trade at very different share prices ($12.48 vs $16.10); PHAR sits at 28% of its 52-week range against 11% for AKTS; our scanner flagged PHAR 4 times in the last 30 days against 71 for AKTS. Everything above is measured from the latest completed session and SEC filings.
- Which of PHAR and AKTS is more active right now?
- Right now PHAR is at about 0.4x its normal volume and AKTS is at about 1.2x, so AKTS is the one drawing unusual attention today. Relative volume (RVOL) compares a stock's volume to its own recent average, so it reads the same way for a megacap and a microcap and is the quickest way to tell which of two similar names is actually in play.
- Is PHAR or AKTS in the stronger trend?
- PHAR is above its 50-day average of $11.03 and below its 200-day average of $13.36; AKTS is below its 50-day average of $17.99 and below its 200-day average of $20.71. PHAR leads 3 of the 5 measures on this page (1 year, vs S&P 500, 3 months, 1 month, trend). A trend is where a stock has been, not a forecast, and nothing here is investment advice.
- Is this comparison data live?
- Prices and % changes are anchored to the latest completed session and split-adjusted, so a reverse split never shows as a fake move. Float is estimated from SEC filings and refreshed as new filings publish.
Trading PHAR or AKTS? Get real-time unusual-volume alerts the moment either one moves, free.
No card · 5 premium daysExplore the market
Free, live market tools. No account required to look.